April 3, 2018
Novocure to Report First Quarter 2018 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months… Read More
learn more
March 20, 2018
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in… Read More
learn more
March 15, 2018
Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
The clinical and preclinical research to be presented includes the application of Tumor Treating Fields in seven cancer types ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14… Read More
learn more
February 22, 2018
Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update
1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016, and an increase of 9 percent versus September 30, 2017 Delivered record quarterly net revenues of $53.7 million, representing 77 percent growth versus December 31, 2016, and 7 percent growth versus… Read More
learn more
February 7, 2018
Novocure Secures New $150 Million Non-Dilutive Term Loan Financing
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in full Novocure’s existing $100 million term loan debt and… Read More
learn more
February 1, 2018
JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients
Health-related quality of life was maintained for a longer period of time in several predefined health scales in EF-14 trial patients treated with a combination of Optune and temozolomide compared to patients treated with temozolomide alone The use of Optune together with temozolomide extended progression free and… Read More
learn more
January 9, 2018
Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue
1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016 Fourth quarter 2017 preliminary net revenues of $53.7 million, reflecting 77 percent growth versus fourth quarter 2016 Fourth quarter and full year 2017 financial results to be reported Thursday,… Read More
learn more